Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Sequenza:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas n. : 159519-65-0
Formula molecolare : C204H301N51O64
Peso Molecolare : 4492
Purezza (HPLC) : 98.0%min.
Aspetto : White to off-white amorphous solid
Singola impurità (HPLC) : 0.5%massimo
Amino Acid Composition : ±10% of theoretical
Peptide Content (N%) : ≥80,0%
Contenuto d'acqua (Karl Fisher) : ≤8,0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
SM (ESI) : Coerente
Mass Balance : 95.0~105,0%
Grado : Grado farmaceutico
Magazzinaggio: Closed, below 2 ~ 8℃ preservation
Utilizzo : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (LOCANDA) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
